Related Experiment Videos
Prednisone administration in recent onset type I diabetes
A Secchi1, M R Pastore, A Sergi
1Istituto Scientifico San Raffaele, Universita' di Milano, Italy.
Journal of Autoimmunity
|October 1, 1990
Summary
Prednisone treatment in recent-onset Type I diabetes mellitus (IDDM) patients helped preserve pancreatic beta-cell function. This led to improved endogenous insulin release and lower insulin needs over two years.
Area of Science:
- Endocrinology
- Immunology
- Metabolic Disorders
Background:
- Type I diabetes mellitus (IDDM) is an autoimmune disease characterized by the destruction of pancreatic beta cells.
- Preserving residual beta-cell function is crucial for improving metabolic control and reducing long-term complications in IDDM patients.
- Current therapeutic strategies for IDDM primarily focus on exogenous insulin replacement, with limited options for preserving endogenous insulin production.
Purpose of the Study:
- To evaluate the efficacy of prednisone in preserving pancreatic beta-cell function in patients with recent-onset Type I diabetes mellitus (IDDM).
- To assess the impact of prednisone on endogenous insulin release and exogenous insulin requirements.
- To compare the effects of prednisone with indomethacin and placebo in managing recent-onset IDDM.
Main Methods:
- A single-blind randomized trial involving 25 patients with recent-onset IDDM (diagnosed within 8 weeks).
- Patients were assigned to receive prednisone (15 mg/day), indomethacin (100 mg/day), or placebo for 8 months.
- Metabolic control was maintained with a multi-injection insulin regimen; endogenous insulin release was assessed via urinary C-peptide levels.
Main Results:
- Prednisone-treated patients required significantly lower insulin doses at 12, 18, and 24 months compared to control groups.
- Urinary C-peptide levels, indicating endogenous insulin release, were significantly higher in the prednisone group at multiple time points (3, 6, 9, 12, 18, and 24 months).
- Minor side effects were noted in the prednisone group, with no significant adverse events reported.
Conclusions:
- Low-dose, long-term prednisone administration effectively preserves and restores endogenous insulin release in patients with recent-onset IDDM.
- Prednisone treatment can lead to reduced exogenous insulin requirements, suggesting a beneficial role in maintaining beta-cell function.
- Further research is warranted to explore the long-term benefits and optimal use of corticosteroids in managing Type I diabetes.